Abstract: PO0850
Outcomes Associated with the Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hospitalized Patients with SARS-CoV-2 Infection
Session Information
- COVID-19: Clinical and Basic Science Characteristics
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Chaudhri, Imran, Stony Brook University Hospital, Stony Brook, New York, United States
- Koraishy, Farrukh M., Stony Brook University Hospital, Stony Brook, New York, United States
- Bolotova, Olena, Stony Brook University Hospital, Stony Brook, New York, United States
- Yoo, Jeanwoo, Stony Brook University Hospital, Stony Brook, New York, United States
- Mallipattu, Sandeep K., Stony Brook University Hospital, Stony Brook, New York, United States
Background
SARS-CoV-2 uses the angiotensin converting enzyme (ACE) receptor for cell entry leading to COVID-19. The use of ACE Inhibitors (ACEIs) and Angiotensin II Receptor Blockers (ARBs) in hypertensive COVID-19 patients remains unclear. Since hypertension is a major comorbidity in COVID19, evaluating the efficacy versus adverse outcomes with the use of ACEI or ARB in patients with COVID-19 is essential.
Methods
In this retrospective single-center study, we analyzed electronic medical record data on 300 patients admitted with COVID-19 disease. Data collection included comorbidities, medications, vital signs, and laboratory values (on admission and during hospitalization). Outcomes included inflammatory burden (calculated using composite scores for multiple markers of inflammation), AKI, admission to the intensive care unit (ICU), need for mechanical ventilation, and mortality. For multivariate analyses, generalized linear model (continuous outcomes) and logistic regression (dichotomous outcomes) were used.
Results
Of the 300 patients, 80 patients (26.7%) had history of ACEI or ARB use prior to admission, with 61.3% (49/80) of these patients continuing the medications during hospitalization. Outpatient users of ACEI or ARB had a higher burden of comorbid disease and increased rates of admission and in-hospital AKI in the descriptive analysis, but not on multivariate analysis (after adjusting for multiple covariates). Continuation of ACEI or ARB inpatient was associated with lower peak C-reactive protein (CRP) levels, peak inflammation score, ICU admission and mortality in the univariate analysis. On multivariate analysis, continuation of these agents during hospitalization predicted lower ICU admissions (OR=0.25, 0.08-0.81, p=0.02), peak CRP (-6.9 ± 3.1 mg/dl, p=0.03) and peak inflammatory score (-2.3 ± 1.1, p=0.04) as compared to their discontinuation.
Conclusion
In hospitalized patients with COVID-19, the use of ACEI or ARBs as an outpatient was not associated with adverse outcomes despite greater comorbid illness in users. The continued use of these medications during hospitalization was also not associated with adverse events, rather it predicted fewer ICU admissions and decreased inflammatory burden.
Funding
- NIDDK Support